Highlights and Quick Summary
- Annual 3Y Operating CF Growth (CAGR) for 2021 was 0.0% (a NaN% decrease from previous year)
- Annual 3Y Operating CF Growth (CAGR) for 2020 was 0.0% (a NaN% decrease from previous year)
- Annual 3Y Operating CF Growth (CAGR) for 2019 was 0.0% (a NaN% decrease from previous year)
Visit stockrow.com/ALNA
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical 3Y Operating CF Growth (CAGR) of Allena Pharmaceuticals, Inc.
Most recent 3Y Operating CF Growth (CAGR)of ALNA including historical data for past 10 years.Interactive Chart of 3Y Operating CF Growth (CAGR) of Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. 3Y Operating CF Growth (CAGR) for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | – | – | – | – | 0.0% |
| 2020 | – | – | – | – | 0.0% |
| 2019 | – | – | – | – | 0.0% |
| 2018 | – | – | – | – | 0.0% |
| 2017 | – | – | – | – | 0.0% |
| 2016 | – | – | – | – | 0.0% |
| 2015 | – | – | – | – | 0.0% |
Business Profile of Allena Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.